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Introduction: Extracellular nucleotides are released and detectable in a high concentration within the tumor
microenvironment. G protein-coupled P2Y2 nucleotide receptor (P2Y2R) is activated equipotently by adenosine
triphosphate (ATP) and uridine 5′-triphosphate (UTP), which mediate proinflammatory responses such as cell migration
and proliferation. However, the role of P2Y2R in the process of cancer metastasis remains unclear. This study aimed to
determine the role of P2Y2R in the proliferation, migration and invasion of highly metastatic MDA-MB-231 breast cancer
cells through crosstalk with endothelial cells (ECs).
Methods: ATP release and P2Y2R activity between high metastatic breast cancer cell MDA-MB-231 and low metastatic
breast cancer cell MCF-7 were compared. Then, the role of P2Y2R on tumor growth and invasion via crosstalk with ECs
was examined in vitro, using MDA-MB-231 cells and ECs transfected with control- or P2Y2R-siRNA, and in vivo, using an
animal model injected with control-shRNA- or P2Y2R-shRNA-transfected MDA-MB-231 cells.
Results: We found that this highly metastatic breast cancer cell line released higher levels of ATP and showed a higher
P2Y2R activity in comparison to a low metastatic breast cancer cell line, MCF-7. In MDA-MB-231 cells, P2Y2R activation
by ATP or UTP increased proliferation at 24 or 72 hours, which was abolished by P2Y2R knock-down. In addition, the
adhesion of MDA-MB-231 cells to ECs and cell migration were both significantly increased by ATP or UTP through
the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in
MDA-MB-231 or ECs but not in cells where P2Y2R was knocked down. Furthermore, ATP- or UTP-mediated activation of
P2Y2R induced MDA-MB-231 invasion through ECs, increased matrix metalloproteinase-9 (MMP-9) activity and vascular
endothelial growth factor (VEGF) production in MDA-MB-231 and induced the phosphorylation of vascular endothelial
(VE)-cadherin in ECs. Tumor growth and metastasis to other tissues were dramatically reduced, and body weight was
increased in mice injected with P2Y2R-shRNA-transfected MDA-MB-231 cells compared to mice injected with control
shRNA-transfected MDA-MB-231 cells.
Conclusion: This study suggests that P2Y2R may play an important role in cancer metastasis via modulation of the
crosstalk between cancer cells and ECs.* Correspondence: hyejungkim@gnu.ac.kr
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Nucleotides, especially ATP, were long thought to be re-
stricted to the intracellular compartment, where they are
involved in biochemical reactions such as energy trans-
actions and nucleic acid synthesis. However, nucleotides
were recently shown to be released from injured or
stressed cells and tissues [1-4] and to mediate various
cellular responses through activation of cell surface P2
receptors, G protein-coupled P2Y receptors (P2YRs) and
ion channel P2X receptors (P2XRs). ATP is also released
and accumulates in a much higher concentration in the
tumor interstitium than in healthy tissues [5], and recent
reports have highlighted the involvement of ATP in
tumor progression. Depending on the dose and the puri-
nergic P2 receptor subtype engaged, ATP can trigger
many different cellular responses, ranging from cell
death to proliferation [6-8]. Among the receptors en-
gaged by extracellular ATP (P2 receptors), the P2Y2R is
most consistently expressed (or overexpressed) by tumor
cells, and it mediates proliferation in many tumors, for ex-
ample, melanoma [9], lung [10], bladder [11] and prostate
cancer [12]; however, controversial phenomena have also
been reported in other tumor types, for example, esopha-
geal [13], colorectal [14] and ovarian cancer [15]. Thus,
further study is needed to determine how P2Y2R affects
tumor progression depending on cancer cell type and the
conditions of the tumor microenvironment.
Breast cancer is the most common cancer diagnosed
in North American and Western European women
[16,17], and Asian populations generally have the lowest
risk, but rates in this population have been steadily in-
creasing. Virtually all patients who die from breast can-
cer have metastatic disease. Cancer metastasis is a
complex process involving the coordinated cellular re-
sponses of both cancer cells and normal cells; invasion
of the stroma, intravasation of the blood vessel, circula-
tion in the blood, lodging and adhesion in the target ca-
pillaries, extravasation from the blood vessels and
proliferation of secondary tumors [18].
Several cell adhesion molecules (CAMs), including
intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1) have been implicated
in cancer growth, and metastasis [19,20]. CAMs are
expressed on a variety of cells, including vascular endothe-
lial cells (ECs), lymphocytes, fibroblasts, hematopoietic
cells and tumor cells [21-24]. Some CAMs, such as
VCAM-1, are expressed preferentially or at higher levels
on the breast cancer endothelium compared to the normal
endothelium [21,25]. ICAM-1 and VCAM-1 are involved
in cell-cell and cell-extracellular matrix (ECM) interac-
tions, and they are mechanistically important for the ex-
travasation of monocytes during inflammation [26] and
cancer cells during metastasis [27,28]. Therefore, the ad-
hesion of circulating tumor cells to the microvascularendothelium of organs at distant sites, such as the liver and
lungs, is an important step in blood-borne metastasis. An-
other important molecule that is critical for tumor metasta-
sis is the transmembrane endothelial adherens junction
(AJ). In ECs, AJs are largely composed of vascular endothe-
lial cadherin (VE-cadherin), an endothelium-specific mem-
ber of the cadherin family of adhesion proteins that binds,
via its cytoplasmic domain, to several protein partners such
as p120, β-catenin and plakoglobin [29]. Thus, we were
specifically interested in the role of P2Y2R in cancer metas-
tasis via the regulation of adhesion molecules (AMs) and
VE-cadherin.
Estrogen receptor (ER)-positive (ER+) breast cancers
generally have a better prognosis and are responsive to
anti-estrogen therapy. In contrast, ER-independent (ER-)
breast cancers are more aggressive, possess high meta-
static potential and are unresponsive to anti-estrogens
[30,31]. As tumor metastasis is considered the main
cause of mortality in cancer patients, it is beneficial to
study how ER- human MDA-MB-231 breast cancer cells
metastasize. In this study, we hypothesized that condi-
tions of the tumor microenvironment, specifically the
high level of ATP released from cancer cells, may affect
tumor progression and metastasis via crosstalk with ECs.
Preliminary data revealed that MDA-MD-231 cells release
ATP at a much higher level than MCF-7 cells; therefore,
in this study, we investigated the role of P2Y2R in cancer
metastasis through crosstalk with ECs using the breast
cancer cell line MDA-MB-231.
Methods
Cell culture
The human breast cancer cell lines MCF-7 and MDA-
MB-231 were obtained from the Korea Cell Line Bank
(Seoul, Korea), and the human umbilical vascular endo-
thelial cell line EA.hy 926 and the spontaneously immor-
talized human normal breast epithelial cell line MCF10A
were originally purchased from the American Type Cul-
ture Collection ATCC, Vanassas, VA, USA). MCF-7 and
MDA-MB-231 were grown in RPMI 1640 supplemented
with 10% FBS, 100 IU/ml penicillin and 10 μg/ml
streptomycin, and MCF10A was grown in DMEM/F-12
medium supplemented with 5% horse serum, 100 U/ml of
penicillin, 100 g/ml of streptomycin, 0.5 g/ml hydrocorti-
sone, 100 ng/ml cholera toxin, 10 g/ml insulin, 10 ng/ml
epidermal growth factor and 1% (w/v) of L-glutamine. EA.
hy 926 was grown in DMEM supplemented with 10%
FBS, 100 IU/ml penicillin and 10 μg/ml streptomycin.
Extracellular ATP release measurements
Cells were incubated for 15 minutes at 37°C with HEPES
buffer (pH 7.4) containing AOPCP, a selective inhibitor
of ecto-5′-nucleotidase. Cells were treated with or with-
out TNF-α for an additional 5 minutes. Supernatants
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was measured with the ENLITEN ATP assay system kit
(Promega, Madison, WI, USA). ATP levels were calcu-
lated based on an ATP standard curve.
Gene silencing with small interferin RNA (siRNA) or small
hairpin RNA (shRNA)
Gene silencing experiments were performed with three in-
dependent P2Y2R-siRNA or shRNA. Cells were trans-
fected with 100 nM control (CTRL) siRNA/P2Y2R siRNA
(Bioneer, Daejeon, Korea) or 10 μg/ml of shRNA (Santa
Cruz; Santa Cruz, CA, USA) in serum-containing medium
using Turbofect® (Thermo Scientific, Rockford, IL, USA).
Gene silencing efficiency was determined by reverse
transcription-polymerase chain reaction (RT-PCR) and
western blot analysis.
RT-PCR
RT-PCR was performed using TOPscript One-step RT
PCR Drymix (Enzynomics, Daejeon, Korea), according
to the manufacturer’s instructions. The primer sets used
were as follows: hP2Y2R, 5′-GTG CTC TAC TTC CTG
GCT-3′ and 5′-CTG AAG TGT TCT GCT CCT AC-3′
and hGAPDH, 5′- TCA ACA GCG ACA CCC ACT
CC-3′ and 5′- TGA GGT CCA CCA CCC TGT TG-3′.
Cell proliferation assay
Cells at the exponential growth phase were seeded at 104
cells per well in 24-well plates. After the indicated treat-
ments, the cells were washed with ice-cold PBS, harvested
and mixed with a 0.4% trypan blue solution. Viable cells in
the cell suspension were counted with a hemacytometer
under a light microscope.
Western blot analysis
Western blot analysis was performed as described previ-
ously [32], with minor modifications. Briefly, aliquots of
50 μg of protein were subjected to 7.5% SDS-PAGE and
transferred onto Hybond-P + polyvinylidene difluoride
membranes (Amersham Biosciences UK Ltd). The
membranes were incubated with primary antibodies; anti-
ICAM-1, −VCAM-1, −P2Y2R (Santa Cruz) or -phosphor-
VE-cadherin (Y658) (Abcam, Cambridge, UK). β-Actin
(Sigma Aldrich, St Louis, MO, USA) was used as loading
control for normalization to the protein expression.
Measurement of intracellular calcium ion concentration
The calcium ion ((Ca2+)i) concentration was measured
as described previously [33]. Briefly, cells were stained
with 5 μM fluo-3-AM and washed with physiological so-
lution (125 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM
HEPES, 5 mM glucose, and 1 mM CaCl2). Then, cells
were treated with ATP or uridine 5′-triphosphate (UTP)
and fluorescent images were scanned every 5 sec using aconfocal microscope (IX70 Fluoview, Olympus, Tokyo,
Japan; excitation wavelength 488 nm, emission wavelength
530 nm). The changes in (Ca2+)i were calculated as follows:
Change in Ca2þ
 
i ¼ Fmax‐F0ð Þ=F0
With F representing the fluorescence intensity; F0, the
basal fluorescence intensity before treatment, and Fmax,
the maximum level of fluorescence intensity, which
occurred after the addition of ATP or UTP).
Adhesion assay
ECs and MDA-MB-231 cells were transfected with CTRL
siRNA or P2Y2R siRNA, as described above. The trans-
fected cells were treated with 10 μM of ATP or UTP for
6 h. ECs were washed three times with fresh serum-free
medium, and MDA-MB-231 cells (7.5 × 105 cells/ml) were
added to the ECs. After 30 minutes at 37°C, cell suspen-
sions were withdrawn, and the ECs were gently washed
with PBS three times. The cells were then counted under
a light microscope, and the number of adhesive cells on
ECs was quantified.
Migration assay
MDA-MB-231 cells were transfected with CTRL siRNA
or P2Y2R siRNA and treated with 10 μM ATP or UTP
for 6 h. Then, 2 × 105 cells were added to the upper
chambers of the inserts, which were placed into a 24-
well plate, and 500 μl of RPMI medium was added to
the lower chambers. The migration chambers were incu-
bated for 24 h in a 37°C cell culture incubator. The non-
migrating cells that remained on the upper surface of
the insert membranes were removed by scrubbing. The
cells that had migrated across the insert-well membrane
were stained with 4′,6-diamidino-2-phenylindole dihy-
drochloride (DAPI), and the cells were counted under a
fluorescence microscope. Each experiment was repeated
three times in triplicate.
Matrigel invasion assay
For invasion assays, the upper chambers of inserts were
coated with 100 μl of Matrigel (1 mg/ml, BD Bioscience,
San Jose, CA, USA), and ECs (2 × 105 cells) were added to
the Matrigel-coated insert wells. MDA-MB-231 cells (2 ×
105 cells per insert) were added to the upper chambers in
serum-free medium, and 500 μl of RPMI medium was
added to the lower chambers. The rest of the procedure
was carried out as described for the migration assay.
Gelatin zymography
Media were concentrated 20-fold using protein concen-
trators (9 K MWCO, Thermo Pierce, Rockford, IL, USA)
and subjected to electrophoresis on 8% PAGE gels con-
taining 1 mg/ml gelatin. Gels were washed twice with
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Blue and de-stained (50% methanol and 10% acetic acid).
Quantitative human vascular endothelial growth factor
(VEGF) immunoassay
The level of VEGF in the conditioned medium from MDA-
MB-231 cells was determined using a VEGF enzyme-linked
immunosorbent assay kit (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s instruction. All
assays were performed on triplicate plates.
Animal experiments
We stably transfected MDA-MB-231 cells with expression
vectors encoding shRNAs targeting P2Y2R (MDA-MB-
231-P2Y2R-shRNA) or with an empty vector (MDA-MB-
231-EV). Athymic nude mice were divided into two
groups and injected subcutaneously with empty vector-
transfected MDA-MB-231 (MDA-MB-231-EV; n = 10)
or P2Y2R-shRNA-transfected MDA-MB-231 (MDA-MB-
231-P2Y2R-shRNA; n = 10) (5 × 10
6 cells/100 μl of serum-
free medium). The experimental protocol was approved
by the Institutional Animal Care and Use Committee at
Gyeongsang National University (approval number:
GLA-120208-M004). Body weights and tumor volumes
were measured every 3 days, starting at 7 days after in-
jection. At the end of 60 days, the mice were sacrificed.
Lung tissue or tumor mass was fixed in 4% paraformal-
dehyde at room temperature, followed by paraffin infil-
tration and embedding. Sections of 5 μm were mounted
onto ProbeOn Plus microscope slides (Fisher Scientific,
Loughborough, UK) and stained with H&E. Immuno-
histochemical analysis was performed using anti-
vimentin, −VCAM-1, −VEGF, −ICAM-1 and CD31
antibodies for lung staining, and H&E and anti-P2Y2R
antibody (Abcam) for tumor staining, and the staining
was examined under a light microscope.
Statistical evaluations
Scanning densitometry was performed using Image Master®
VDS (Pharmacia Biotech Inc, San Francisco, CA, USA).
The treatment groups were compared using one-way ana-
lysis of variance and the Scheffe post-hoc test. All data were
expressed as the mean ± standard error of the mean (SEM).
Statistical analysis of the frequency of lung metastasis in the
two animal groups was performed by Fisher’s exact test.
P <0.05 was considered statistically significant.
Results
MDA-MB-231 highly metastatic breast cancer cells release
higher levels of ATP and show a higher P2Y2R activity
than the low metastatic breast cancer cell line MCF-7
or normal cells
First, we compared the levels of ATP released into the
extracellular medium by various cell types. In normalconditions, the highly metastatic breast cancer cell line
MDA-MB-231 released markedly more ATP in compari-
son to ECs, MCF10A (normal breast epithelial cells) and
MCF-7 (low metastatic breast cancer cell). In addition,
TNF-α, an essential factor in tumor progression and
metastasis [34,35], significantly enhanced the release
of ATP, especially in MDA-MB-231 (Figure 1A). More-
over, RT-PCR revealed that P2Y2R mRNA was present
in ECs, MCF10A, MCF7 and MDA-MB-231. Interest-
ingly, P2Y2R mRNA levels were higher in the MCF-7
and MDA-MB-231 as compared to normal ECs or
MCF-10A, and there was no significant difference be-
tween P2Y2R mRNA expression in MCF-7 and MDA-
MB-231 (Figure 1B). To further compare P2Y2R activity
between MCF-7 and MDA-MB-231, we measured the
intracellular Ca2+ level (Ca2+)i in response to agonist ATP
or UTP. ATP or UTP (10 μM) elicited the immediate and
rapid augmentation in (Ca2+)i in MDA-MB-231, which was
significantly reduced in P2Y2R-knocked-down MDA-MB-
231. Interestingly, the transient elevation of (Ca2+)i levels in
MCF-7 were much lower than MDA-MB-231 (Figure 1C),
suggesting the difference in P2Y2R activity in response to
nucleotides between MCF-7 and MDA-MB-231.
P2Y2R activation by ATP or UTP increases proliferation,
migration and expression of adhesion molecules in
MDA-MB-231 cells
We transfected MDA-MB-231 with scrambled RNA or
P2Y2R shRNA to elucidate the role of P2Y2R in the prolif-
eration of breast cancer cells. After confirming the effi-
ciency of P2Y2R shRNA at the mRNA and protein levels
(Figure 2A), cells were treated with ATP or UTP (1, 10,
100 μM) for 24 h. P2Y2R activation by ATP or UTP signifi-
cantly increased MDA-MB-231 proliferation at a low dose
(1 μM), whereas the proliferation of P2Y2R-shRNA-trans-
fected MDA-MB-231 was not affected by treatment with
ATP or UTP (Figure 2B). In addition, we assessed the effect
of P2Y2R on ICAM-1 and VCAM-1 expression after stimu-
lating MDA-MB-231 with ATP or UTP and found that both
ATP and UTP upregulated the expression of ICAM-1 and
VCAM-1 at the indicated doses (Figure 2C), whereas the
expression of ICAM-1 and VCAM-1 stimulated by 10 μM
ATP or UTP was inhibited in MDA-MB-231 transfected
with P2Y2R shRNA (Figure 2D). Moreover, P2Y2R activation
by ATP or UTP induced MDA-MB-231 cell migration
across the insert-well membrane, and this effect was blocked
in P2Y2R knocked down MDA-MB-231 (Figure 2E).
Nucleotides released from MDA-MB-231 cells induce the
expression of AMs in ECs, increasing the adhesion of
MDA-MB-231 cells to ECs and enhancing invasion through
P2Y2R activation
Next, we investigated the effect of ATP or UTP on the
expression of AMs in ECs, the adhesion of cancer cells
Figure 1 ATP release and P2Y2R expression and activity in various cell types. (A) The amount of ATP released into the extracellular
medium was measured as described in Methods. Significance compared to MDA-MB-231, **P <0.01. (B) Total RNA was collected from endothelial
cells (ECs), MCF10A, MCF-7 and MDA-MB-231, and P2Y2R (200 bp) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (125 bp) mRNA
expression was analyzed by RT-PCR. The results were confirmed by at least two independent experiments. (C) Intracellular Ca2+ levels were determined
in MDA-MB-231 and MCF-7 to measure the P2Y2R activity. Arrows indicate the points at which ATP or uridine 5′-triphosphate (UTP) (10 μM) was added.
The net change in Ca2+ levels was normalized to (Fmax-F0)/F0. Significance compared to ATP or UTP, **P <0.01.
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MDA-MB-231 released high amounts of ATP (Figure 1A),
we tested whether nucleotides released from these cells
could increase the expression of AMs in ECs. When
ECs were treated with conditioned media (CM) from
MDA-MB-231 for 6 h, ECs increased ICAM-1 and
VCAM-1 expression was observed, although such ex-
pression was abolished in the presence of apyrase, anenzyme that rapidly hydrolyzes extracellular nucleotide
(Figure 3A). In addition, ATP or UTP treatment dose-
dependently increased ICAM-1 and VCAM-1 expression
in ECs (Figure 3B). Furthermore, P2Y2R knockdown
(Figure 3C) in ECs abolished the ATP- or UTP-
mediated ICAM-1 and VCAM-1 expression in ECs
(Figure 3D). Moreover, adhesion of MDA-MB-231 to
ECs that were stimulated with ATP or UTP (10 μM)
Figure 2 P2Y2R activation by ATP or UTP induced MDA-MB-231 cell proliferation, migration and expression of adhesion molecules.
(A, B) Control- or P2Y2R-shRNA-transfected MDA-MB-231 were treated with various concentrations of ATP or UTP, as indicated. After 24 h, cell
proliferation was determined by trypan blue exclusion assay. Significance compared to the control, **P <0.01. (C) MDA-MB-231 were treated with
the indicated doses of ATP or UTP for 6 h. ICAM-1, VCAM-1 and β-actin expression levels were analyzed by western blotting. (D) Control- or
P2Y2R-shRNA-transfected MDA-MB-231 were treated with ATP or UTP (10 μM) for 6 h, and ICAM-1 (88 to 110 KDa) and VCAM-1 (130 KDa)
expression levels were determined as described previously. Significance compared to the control, **P <0.01; significance compared to ATP
or UTP, #P <0.05. (E) Control- or P2Y2R-shRNA-transfected MDA-MB-231 were treated with ATP or UTP (10 μM). Six hour later, the cells were
harvested, and seeded onto cell culture inserts. After 24 h, the cancer cells that had migrated across the insert well membrane were stained with
DAPI, and the number of migrated cells was counted under a fluorescence microscope and quantified. Significance compared to the control, **P <0.01;
significance compared to ATP or UTP, ##P <0.01.
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cells, whereas transfection of P2Y2R siRNA in ECs and
MDA-MB-231 markedly reduced the effect of ATP or
UTP on breast cancer cell-EC adhesion (Figure 3E). Next,
to investigate the role of P2Y2R in the invasion of MDA-
MB-231 through ECs, we performed Matrigel invasionassays. MDA-MB-231 cells were pretreated with ATP or
UTP for 6 h to induce AMs expression (ICAM-1 and
VCAM-1) and were then harvested and seeded onto ECs-
coated insert wells. ATP or UTP treatment increased the
invasion of MDA-MB-231 through ECs but not through
P2Y2R knocked down ECs (Figure 3F). Because MDA-MB-
Figure 3 P2Y2R activation by ATP or uridine 5′-triphosphate (UTP) regulated the expression of adhesion molecules in endothelial cells
(ECs) and increased the adhesion and invasion of MDA-MB-231 cells in ECs. (A) Conditioned media (CM) was obtained from MDA-MB-231
cultured in serum-free media for 16 h with or without apyrase (10 U/ml). Then, ECs were treated with CM from MDA-MB-231 for 6 h, and ICAM-1 and
VCAM-1 expression was determined by western blotting. Significance compared to the control, *P <0.05; significance compared to CM, #P <0.05. (B) ECs
were treated with the indicated doses of ATP or UTP for 6 h, and protein expression levels were determined. (C, D) Control- or P2Y2R-siRNA-transfected
ECs were treated with ATP or UTP (10 μM) for 6 h, and ICAM-1 and VCAM-1 protein expression levels were determined. Significance compared to the
control, *P <0.05, **P <0.01; significance compared to ATP or UTP, #P <0.05, ##P <0.01. (E, F) Control- or P2Y2R-siRNA-transfected MDA-MB-231 and ECs
were treated with ATP or UTP (10 μM) for 6 h. Then, MDA-MB-231 were seeded onto ECs (E) or ECs in Matrigel-coated cell culture inserts (F). After
30 minutes the remaining cell suspension (MDA-MB-231) was withdrawn, and the number of adherent cells was counted under a light
microscope and quantified (E). After 24 h, the numbers of cancer cells that had invaded through the EC-Matrigel-coated insert membranes
were evaluated by staining with DAPI and quantified (F). Significance compared to the control, **P <0.01; significance compared to ATP or
UTP, ##P <0.01.
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we compared the effects of nucleotides on the invasion of
low or highly metastatic breast cancer cells. MDA-MB-231
showed a higher invasion than MCF-7 in basal level,which was abolished in the presence of apyrase. ATP or
UTP increased the invasion of MCF-7, however which
was much lower than that of MDA-MB-231 (Additional
file 1: Figure S1).
Jin et al. Breast Cancer Research 2014, 16:R77 Page 8 of 14
http://breast-cancer-research.com/content/16/5/R77P2Y2R activation mediates angiogenesis through the
regulation of matrix metalloproteinase (MMP) activity and
vascular endothelial growth factor (VEGF) production in
MDA-MB-231 cells
Because angiogenesis is a prerequisite for tumor growth
and metastasis, and MMPs and VEGF are well-known to
be involved in the angiogenesis, thus, we investigated
the effects of P2Y2R activation on MMP activity and
VEGF production in MDA-MB-231. ATP or UTP treat-
ment increased MMP activity, especially that of MMP-9.
In contrast, ATP or UTP (10 μM) failed to increase
MMP-9 activity in MDA-MB-231 in which P2Y2R was
knocked down (Figure 4A). Moreover, Figure 4B shows
that VEGF production was significantly increased in
MDA-MB-231 treated with ATP or UTP (10 μM) for 24 h
compared to untreated cells. As expected, shRNA-
mediated inhibition of P2Y2R significantly suppressed the
production of VEGF induced by ATP or UTP (Figure 4B).
ATP or UTP modulates tyrosine phosphorylation of VE-
cadherin in ECs, indicating that P2Y2R may facilitate and
increase EC permeability and breast cancer cell invasion
through ECs
Cancer cell invasion through ECs could be regulated by
tyrosine phosphorylation of VE-cadherin in ECs [29],
and thus, we determined whether activation of P2Y2R by
ATP or UTP would lead to the phosphorylation of a
tyrosine residue (Y658) of VE-cadherin in ECs. Our re-
sults indicated that ATP or UTP treatment increased the
phosphorylation of VE-cadherin (Y658) at very early time
points (5 or 10 minutes, respectively), which subsequently
reached a maximum level at 30 minutes (Figure 5A) and
was sustained until later times. However, ATP and UTP
failed to increase the phosphorylation of Y658 VE-cadherin
in P2Y2R-knocked-down ECs (Figure 5B).
P2Y2R is involved in the tumor growth and metastasis of
MDA-MB-231 breast cancer cells in an in vivo mouse model
To confirm the role of P2Y2R in in vivo tumor progression,
nude mice were injected with control-shRNA-transfected
MDA-MB-231 cells (MDA-MB-231-EV) or P2Y2R-
shRNA-transfected MDA-MB-231 cells (MDA-MB-
231-P2Y2R shRNA), and tumor volumes and body
weights were measured every 3 days for 60 days. P2Y2R
knockdown in the tumor of MDA-MB-231-P2Y2R-
shRNA-injected mice was still functional after 60 days
(Additional file 2: Figure S2). Tumor growth in mice
injected with MDA-MB-231-P2Y2R-shRNA was signifi-
cantly decreased, and their body weights were increased
compared to those of mice injected with MDA-MB-
231-EV by 2 weeks post-injection (Figure 6A-C). In our
previous report [32] and the present study, MDA-MB-
231-EV-injected mice showed a high number of cancer
cells that had invaded into the lungs (9 of 10 mice),however, this was also seen in 3 of 10 mice injected with
MDA-MB-231-P2Y2R-shRNA (Figure 6D) (P = 0.018,
Fisher’s exact test). Additionally, we examined the lungs of
tumor-bearing mice for MDA-MB-231 metastatic lesions
using an antibody specific for human vimentin as de-
scribed by Luga et al. [36]. Interestingly, vimentin expres-
sion was detected in the lungs of MDA-MB-231-EV-
injected mice but not in the lungs of mice injected with
MDA-MB-231-P2Y2R-shRNA. Furthermore, AMs (ICAM-
1 and VCAM-1) and angiogenesis markers (CD31 and
VEGF) expressions were also detected in the lungs of
MDA-MB-231-EV-injected mice, but not in those of
MDA-MB-231-P2Y2R-shRNA-injected mice (Figure 6E).
Discussion
Cancer metastasis requires communication between
tumor cells and ECs that culminates in the disruption of
EC-EC contacts and degradation of the vascular basement
membrane. However, the molecular mechanisms that fa-
cilitate such communication are not fully understood. Re-
cently, it was reported that the tumor microenvironment
affects tumor progression and the formation of metastases
by mediating interactions between tumor cells, their se-
creted factors and the endothelium [37,38]. Considering
that tumor metastasis is the main cause of mortality in
cancer patients [39], it is important to investigate the dif-
ferences between highly metastatic cancer cells and low
metastatic cancer cells, such as MDA-MB-231 and MCF-
7, respectively, to understand how highly metastatic can-
cer cells communicate with ECs. It was also reported that
malignant tumors trigger a strong inflammatory response
and are frequently characterized by the formation of dif-
fuse necrotic foci. Under these conditions, ATP is released
from the malignant tumor and accumulates at high con-
centrations in the tumor interstitium to induce tumor pro-
gression. Thus, we first sought to determine the amount
of ATP released from MDA-MB-231 and MCF-7. Interest-
ingly, the highly metastatic breast cancer cell line MDA-
MD-231 released significantly more ATP than the less
metastatic MCF-7 cell line or normal epithelial cells or
ECs, and this effect was dramatically enhanced by TNF-α.
These findings are strongly supported by those of Kawai
et al., who also reported that the supernatant from MDA-
MB-231, but not MCF-7, stimulated significantly elevated
expression of ICAM-1 in ECs [40]. Although these au-
thors identified the responsible substance from the super-
natant as ATP, they did not show the exact receptor
through which ATP may act but suggested that this may
occur via a purinergic P2X or P2Y receptor. Among the
receptors engaged by extracellular ATP (P2 receptors),
P2Y2R is the one most overexpressed in tumor cells and
mediates cell proliferation in most cancer cell types [41].
ATP also activates P2X7R, and this interaction is known
to alter cancer cell function. However, the role of P2X7R
Figure 4 Matrix metalloproteinase (MMP) activity and vascular endothelial growthe factor (VEGF) production in MDA-MB-231 cells was
regulated by P2Y2R activation mediated by ATP or uridine 5′-triphosphate (UTP). (A) MDA-MB-231 were treated with the indicated doses of
ATP or UTP for 6 h. MMP gelatinase activities were measured in conditioned media (CM) as described in Methods. Control- or P2Y2R-shRNA-transfected
MDA-MB-231 were treated with 10 μM of ATP or UTP. After 6 h, MMP gelatinase activities were determined in the CM and quantified (MMP-9; 92 KDa).
Significance compared to the control, **P <0.01; significance compared to ATP or UTP, #P <0.05, ##P <0.01. (B) Control- or P2Y2R-shRNA-transfected
MDA-MB-231 were treated with 10 μM ATP or UTP for 24 h, and the concentration of VEGF from the media was determined using a quantitative VEGF
ELISA. Significance compared to the control, **P <0.01; significance compared to ATP or UTP, ##P <0.01.
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P2X7R activation by ATP produces a trophic, growth-
promoting effect [8], but according to the review by White
and Burnstock [41], P2X7R may also decrease the number
of cancer cells in contrast to P2Y2R. In this respect, inves-
tigating the role of P2Y2R and its potential involvement in
cancer metastasis is important for developing effective an-
ticancer strategies. Thus, in this study, we aimed todetermine the role of P2Y2R, which is activated equipo-
tently by ATP and UTP, in cancer cell metastasis, and we
found that P2Y2R activation by ATP or UTP increased
MDA-MB-231 cell proliferation and AM-mediated migra-
tion and also stimulated AM expression in ECs, resulting
in increased adhesion of MDA-MB-231 to ECs. Moreover,
P2Y2R activation by ATP or UTP increased MMP-9 activ-
ity and VEGF production in MDA-MB-231, VE-cadherin
Figure 5 ATP or uridine 5′-triphosphate (UTP) induced the phosphorylation of vascular endothelial (VE)-cadherin at tyrosine residue
Y658 in endothelial cells (ECs). (A) ECs were treated with ATP or UTP (10 μM) for different periods of time (5 to approximately 360 minutes).
Y658-phosphorylated VE-cadherin (88 KDa), VE-cadherin (130 KDa) and β-actin protein expression levels were determined by western blotting.
(B) ECs were transfected with control- or P2Y2R-siRNA, and the ECs were treated with ATP or UTP (10 μM) for 30 minutes. Protein expression
levels were determined as described previously. Significance compared to the control, **P <0.01; significance compared to ATP or UTP, #P <0.05;
##P <0.01.
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through ECs.
Finally, the role of P2Y2R in cancer progression was
confirmed using a P2Y2R siRNA in vitro transfection sys-
tem (MDA-MB-231 and ECs) and an in vivo mice model
in which animals were injected with P2Y2R-shRNA-trans-
fected MDA-MB-231 cells. Interestingly, there was no sig-
nificant difference in P2Y2R expression levels between
MCF-7 and MDA-MB-231, and MCF-7 also showed an
increase in (Ca2+)i. However, the transient elevation of
(Ca2+)i levels in MCF-7 were much lower than MDA-MB-
231 in response to ATP or UTP (Figure 1C), suggesting
the higher P2Y2R activity in MDA-MB-231 than MCF-7.
Chadet et al. [42] also showed the expression and activity
of P2Y2Rs in MCF-7 breast cancer cells promoting their
migration. However, they did not show the ability ofMCF-7 to invade through Matrigel and ECs. According to
our data (Additional file 1: Figure S1), MDA-MB-231
showed a higher invasion than MCF-7 in basal level, which
was abolished in the presence of apyrase. ATP or UTP in-
creased the invasion of MCF-7, however which was much
lower than that of MDA-MB-231. Actually, Ca2+ signals
following UTP/ATP stimulation in MDA-MB-231 was sig-
nificantly but not completely reduced by P2Y2R siRNA,
which is possibly due to the incomplete knock-down effi-
ciency of P2Y2R. Various studies have also reported
that P2Y2R is most consistently expressed by tumor
cells, however the role of P2Y2R on the tumor growth
is controversial depending on tumor types [9-15].
Thus, our results propose that functional P2Y2R acti-
vation in highly metastatic breast cancer cells MDA-
MB-231 mediate the signaling pathways that are
Figure 6 Inhibition of P2Y2R reduced breast cancer cell growth and metastasis in an in vivo mouse model. Athymic nude mice were
divided into two groups and injected subcutaneously with empty vector-transfected MDA-MB-231 (MDA-MB-231-EV; n = 10) or P2Y2R-shRNA-transfected
MDA-MB-231 (MDA-MB-231-P2Y2R-shRNA; n = 10) (5 × 10
6 cells/100 μl of serum-free medium). (A) MDA-MB-231-EV-injected or MDA-MB-231-P2Y2R-
shRNA-injected animals were sacrificed at day 60, and the tumors were extracted. Body weights (B) and tumor volumes (C) were measured every 3 days
during tumor development (*P <0.05, **P <0.01 compared to the MDA-MB-231-EV-injected group). (D) Incidence of lung metastasis was examined in
MDA-MB-231-EV- or MDA-MB-231-P2Y2R-shRNA-injected mice, and representative HE-stained sections are shown (*P < 0.05, compared to the MDA-MB-
231-EV-injected group). (E) Lung tissue sections were stained with anti-vimentin, ICAM-1, VCAM-1, CD31 and VEGF antibodies.
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examine the signaling differences between MDA-MB-
231 and MCF-7.
CAMs take part in intercellular and ECM interac-
tions in cancer, and they play a pivotal role in cancer
recurrence, invasiveness and the development of dis-
tant metastases. This study demonstrated that P2Y2R
activation by ATP or UTP markedly induced ICAM-1
and VCAM-1 expression at very low doses (from
0.1 μM) in MDA-MB-231 and ECs. Furthermore,
MDA-MB-231 or ECs in which P2Y2R was knocked
down failed to induce ICAM-1 or VCAM-1 expression.
In addition, the supernatant from MDA-MB-231 sig-
nificantly increased ICAM-1 and VCAM-1 expressionin ECs, which was diminished in the presence of apy-
rase, an enzyme that rapidly hydrolyzes extracellular
nucleotides. Thus, these data suggest that P2Y2R acti-
vation by nucleotides released from MDA-MB-231 in-
duces AMs by MDA-MB-231 and ECs, which may play
an important role in cancer cell migration, cancer cell
adhesion to ECs and cancer cell invasion through ECs.
The concentration of ATP in the extracellular space is
the net result of release and degradation; therefore, the
actual concentration of ATP released from cancer cells
could be higher than the extracellular ATP concentra-
tion measured in the tumor milieu. Pellegatti et al. [5]
measured real-time ATP concentrations within the
tumor microenvironment using a chimeric plasma
Figure 7 Schematic representation of the proposed role of P2Y2R in MDA-MB-231 breast cancer cell progression.
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ported that the extracellular ATP concentration was in
the hundred micromolar range in the tumor extracellu-
lar milieu, whereas it was undetectable (submicromolar)
in healthy tissues. In this study, the concentration of
ATP released from MDA-MB-231 was approximately
50 nM and 100 nM in the untreated condition and the
TNF-α-stimulated condition, respectively. As men-
tioned previously, ATP or UTP was able to induce
ICAM-1 and VCAM-1 expression at very low doses
(100 nM) via P2Y2R activation, which indicates that
ATP levels within the tumor microenvironment are suf-
ficient to stimulate P2Y2R in MDA-MB-231 or ECs.
Endothelial permeability is one of the main factors
influencing intravasation, extravasation and invasion in
cancer metastasis. ECs possess several molecular
mechanisms by which vascular permeability can be
modulated, including the organization of adherens
junctions, and in several cases, the targeting of VE-
cadherin specifically. Furthermore, the phosphoryl-
ation, cleavage and internalization of VE-cadherin are
thought to affect endothelial permeability [29], and
VEGF and MMPs are well-known factors that mediate
invasion through ECM remodeling [43,44] and the
modulation of EC permeability [45,46]. In this study,
we determined the effect of P2Y2R on the phosphoryl-
ation of VE-cadherin (Y658) in ECs and the MMP-9
activity and VEGF production in MDA-MB-231. Ac-
cording to Schumacher et al. [47], they also showed
that ATP release from tumor cell-activated plateletsactivated P2Y2Rs on ECs to promote the extravasation
of cancers at metastatic sites. However, they didn’t de-
scribe the mechanism for the tumor cell extravasation
through endothelial cells. Our results showed that
P2Y2R activation by ATP or UTP induced MMP-9 ac-
tivity, VEGF production and VE-cadherin phosphoryl-
ation, and these effects of P2Y2R suggest that it plays
an important role in promoting cancer metastasis.
Taken together, our findings suggest for the first time
that MDA-MB-231 highly metastatic breast cancer
cells release higher levels of ATP and show higher
P2Y2R activity in comparison to MCF-7 low metastatic
breast cancer cells, and that ATP-mediated activation
of P2Y2R plays an important role in cancer metastasis
by modulating crosstalk between cancer cells and ECs.
Conclusion
MDA-MB-231 highly metastatic breast cancer cells
release higher levels of ATP in comparison to MCF-7
low metastatic breast cancer cells, and ATP-mediated
activation of P2Y2R plays an important role in cancer
metastasis by modulating crosstalk between cancer
cells and ECs (Figure 7).Additional files
Additional file 1: Figure S1. A) ECs were added to Matrigel-coated
24-well cell culture inserts. MCF-7 and MDA-MB-231 cells were treated
with apyrase (10 U/ml), ATP or UTP (10 μM) for 6 h and seeded onto ECs
in Matrigel-coated cell culture inserts. After 24 h, the numbers of cancer
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http://breast-cancer-research.com/content/16/5/R77cells that had invaded through the EC-Matrigel-coated insert membranes
were evaluated by staining with DAPI. B-C) The number of cells that
invaded through the membrane was quantified by counting cells under
a fluorescence microscope. Values represent the means ± SEM of 3
independent experiments (B, **P < 0.01; C, significance compared to the
control of MCF-7, **P < 0.01; significance compared to the control of
MDA-MB-231, ##P < 0.01).
Additional file 2: Figure S2. Tumor tissue sections from MDA-MB-231-EV-
and MDA-MB-231-P2Y2R-shRNA-injected mice were stained with H&E and
anti-P2Y2R antibody (400x or 200x magnification).
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